A New Jersey state court jury recently found in favor of Merck & Co., Inc. rejecting the claims of a woman who alleged that her dental and jaw related problems were caused by the osteoporosis drug FOSAMAX. The case entitled, Rosenberg v. Merck, was the first state court case to go to trial in the coordinated New Jersey FOSAMAX litigation. This is the fourth FOSAMAX case to go to verdict; however, the first three trials were before Judge John F. Keenan in the U.S. District Court for the Southern District of New York as part of the federal multidistrict litigation proceedings. Two of these federal trials also resulted in a defense verdict for Merck. In the third case, which was originally a mistrial, Merck was hit with an $8 million jury award. This verdict is now on appeal. Presently, there are more than 1,100 FOSAMAX jaw lawsuits against Merck in either state or federal court. Although these findings are not binding, these early verdicts may help parties gauge the strength of their arguments in future FOSAMAX trials against Merck.